Shilpa Medicare’s 238% Rally Now Faces a Real Earnings Test

Shilpa Medicare share price up 238% in 2026. Q1FY27 revenue up 43% YoY to Rs 469 crore. PAT up 115% to Rs 101 crore, aided by a one-time tax reversal. EBITDA margin steady at 30%.

Shilpa Medicare has been one of the standout pharmaceutical stories of 2026, and its latest quarterly results give investors a genuine data point to test whether the rally has been backed by real operational improvement or simply riding sector-wide sentiment.

Click Here – Get Free Investment Predictions

A Fourth Straight Record Quarter

Shilpa Medicare posted its highest-ever quarterly revenue and EBITDA for the fourth consecutive quarter in Q1FY27, the period ended June 30, 2026. Consolidated revenue came in at Rs 469 crore, up 43 percent from Rs 328 crore a year earlier, while EBITDA rose 42 percent to Rs 139 crore, holding the EBITDA margin steady at 30 percent. Gross margin for the quarter stood at a healthy 71 percent.

Reported profit after tax jumped 115 percent year-on-year to Rs 101 crore, though a meaningful part of that increase, roughly Rs 26.84 crore, came from a one-time deferred tax liability reversal rather than pure operational improvement. Investors should treat the headline profit growth with that context in mind, since the underlying operating performance, while genuinely strong, grew at a somewhat more modest pace than the reported bottom line suggests.

Also read – Vedanta Power Set to Enter Nifty 500: Should Investors Take Note?

Also read – Why TVS Group’s Venu Srinivasan Is at the Centre of the Tata Sons IPO Fight

Where the Growth Is Coming From

Shilpa Medicare’s revenue mix remained diversified across its three operating verticals: APIs contributed 47 percent of revenue, formulations 42 percent, and biologics 11 percent. Formulations was the standout performer, growing over 100 percent year-on-year, with the US market contributing Rs 45 crore and Europe contributing Rs 57 crore in formulations revenue. API revenue was supported by steady captive demand from the company’s own formulation business alongside improving traction in third-party API sales.

Check Live Stock Fundamentals on Univest Screener

The Pipeline Behind the Earnings Test

The company’s growth narrative increasingly rests on a broader pipeline beyond its traditional API business. Its Aflibercept biosimilar is on track for an India launch in FY27, Nivolumab has been partnered with Orion for the European market, and multiple CDMO programmes are progressing, including one entering human trials in FY27. The company has also flagged strategic investments in novel areas such as recombinant human albumin and an ADC biosimilar, both targeted to enter human studies in FY27.

Management has indicated that the bulk of the company’s significant capital investments are largely behind it, with existing capacity in biologics and formulations offering headroom to drive future growth without requiring major fresh capital expenditure. The CDMO business alone now counts over 20 customers and more than 25 new chemical entity programmes, including three late-stage programmes expected to commercialise in FY28.

Why the Earnings Test Matters Now

After a 238 percent rally, Shilpa Medicare‘s valuation already prices in a meaningful amount of future growth. That makes the durability of this quarter’s revenue and margin trends more important than the headline numbers themselves. A one-off tax benefit inflating reported profit, alongside a still-small biologics contribution at 11 percent of revenue, means the stock’s next few quarters will need to show that formulations growth and biologics monetisation continue at pace, rather than proving to be a single standout quarter.

Download the Univest iOS App or Univest Android App to track your portfolio on the go.

Conclusion

The Shilpa Medicare share price reflects genuine operational momentum, record revenue, expanding formulations, and a broadening pipeline across biologics and CDMO, but the scale of the 2026 rally means the stock now needs to keep delivering rather than simply beating a low base. Investors should track formulations and biologics revenue trends specifically in coming quarters, since those are the segments management itself is betting the next leg of growth on.

The information in this article is for educational purposes only and must not be treated as investment advice. Stock markets are subject to risk, and past performance is not indicative of future results. Please verify all data independently and consult a registered investment adviser before making any investment decision. Univest Communications Private Limited, SEBI Registered Research Analyst, Registration No. INH000013776.

Frequently Asked Questions

How much has Shilpa Medicare’s share price risen in 2026?

Ans. Shilpa Medicare’s share price has risen 238 percent in 2026, making it one of the standout pharmaceutical performers of the year.

What were Shilpa Medicare’s Q1FY27 results?

Ans. Consolidated revenue rose 43 percent year-on-year to Rs 469 crore, EBITDA grew 42 percent to Rs 139 crore, and profit after tax jumped 115 percent to Rs 101 crore, aided partly by a one-time tax reversal.

Was Shilpa Medicare’s profit growth entirely from its core business?

Ans. No, a meaningful part of the 115 percent profit growth came from a one-time deferred tax liability reversal of about Rs 26.84 crore, rather than purely from operational improvement.

Which segment grew fastest for Shilpa Medicare in Q1FY27?

Ans. Formulations was the fastest-growing segment, up over 100 percent year-on-year, with the US and Europe markets contributing Rs 45 crore and Rs 57 crore respectively.

What is Shilpa Medicare’s biologics pipeline?

Ans. The company’s biologics pipeline includes an Aflibercept biosimilar set for an India launch in FY27, a Nivolumab partnership with Orion for Europe, and early-stage work on recombinant human albumin and an ADC biosimilar.

Does Shilpa Medicare need more capital investment for growth?

Ans. Management has indicated that the bulk of major capital investments are largely behind the company, with existing capacity in biologics and formulations expected to support growth without significant new capex.

Where can I check Shilpa Medicare’s live share price and fundamentals?

Ans. You can track live price data and fundamentals for Shilpa Medicare using the Univest Screener.